Trial of PXD101 in Combination With Idarubicin to Treat Acute Myeloid Leukemia (AML) Not Suitable for Standard Intensive Therapy
This study has been completed.
Sponsor:
TopoTarget A/S
Information provided by (Responsible Party):
TopoTarget A/S
ClinicalTrials.gov Identifier:
NCT00878722
First received: April 7, 2009
Last updated: January 28, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | May 2009 |
| Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Certification or Request for Extension to Delay Results Received: | December 18, 2012 |